TABLE 1.
Home monitoring | No home monitoring | p-value | |
Patients | 55 | 110 | |
Age years | 61 (45–69) | 59 (46–70) | 0.909 |
Female | 27 (49) | 53 (48) | 0.912 |
Medical history | |||
Charlson comorbidity index | 3 (1–6) | 3 (1–5) | 0.989 |
Hypertension | 22 (40) | 36 (33) | 0.356 |
Diabetes mellitus | 4 (7) | 6 (5) | 0.733 |
Coronary heart disease | 0 (0) | 13 (12) | 0.005 |
COPD | 8 (15) | 13 (12) | 0.620 |
Malignancy | 17 (31) | 40 (36) | 0.487 |
Chronic kidney disease | 6 (11) | 12 (11) | 1.000 |
Immunocompromised | 23 (42) | 44 (40) | 0.823 |
COVID-19 diagnostics | |||
Nasopharyngeal swabs | 44 (80) | 85 (77) | 0.689 |
CT scan | 18 (33) | 35 (32) | 1.000 |
Underwent COVID-19 diagnostics | 46 (84) | 90 (82) | 0.772 |
COVID-19 outcomes | |||
Nasopharyngeal swab positive | 13 (24) | 7 (6) | 0.002 |
CO-RADS ≥4 | 8 (15) | 3 (3) | 0.004 |
Confirmed COVID-19 | 16 (29) | 9 (8) | <0.001 |
Primary outcomes | |||
Hospital admission (total) | 5 (9) | 30 (27) | 0.007 |
Short stay admission | 0 (0) | 25 (23) | <0.001 |
Length of home monitoring days | 4 (3–7) | ||
Secondary outcomes | |||
Stayed at home | 47 (85) | 76 (69) | 0.023 |
Bed occupancy days per 100 patients | 20 | 47 |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. CT: computed tomography; CO-RADS: COVID-19 Reporting and Data System.